Patents Examined by Kimberly Ballard
  • Patent number: 10675328
    Abstract: Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin ?4?1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 9, 2020
    Assignee: Children's Hospital Medical Center
    Inventor: Ying Sun
  • Patent number: 10676525
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: June 9, 2020
    Assignee: ALECTOR LLC
    Inventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
  • Patent number: 10669523
    Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 2, 2020
    Assignee: Gloriana Therapeutics, Inc.
    Inventors: Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
  • Patent number: 10662239
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: May 26, 2020
    Assignee: MedImmune Limited
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Patent number: 10653759
    Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, inhibiting, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: May 19, 2020
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Chuanhai Cao, Xiaoyang Lin
  • Patent number: 10640557
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 5, 2020
    Assignee: Neuracle Sceince, Inc.
    Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
  • Patent number: 10633433
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: July 2, 2016
    Date of Patent: April 28, 2020
    Assignees: PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Patent number: 10626169
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: April 21, 2020
    Assignee: Sanofi
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Patent number: 10611844
    Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (EGFR) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain. The invention relates in more detail to compositions comprising inhibitors of EGFR.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: April 7, 2020
    Assignee: Sykehuset Sørlandet HF
    Inventors: Christian Kersten, Marte Grønlie Cameron, Svein Mjåland
  • Patent number: 10603367
    Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: March 31, 2020
    Assignee: Probiodrug AG
    Inventors: Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies
  • Patent number: 10590198
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: March 17, 2020
    Assignee: Alector LLC
    Inventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
  • Patent number: 10584163
    Abstract: The invention relates to the monoclonal antibody 1G2, the hybridoma cell line H-1 G2 characterized by DSM ACC3248, and the epitope TPP comprising the amino acids threonine, proline, proline. The invention further relates to a method for producing a monoclonal antibody against a TAU protein fraction that is non-phosphorylated in positions T175 and/or T181 and/or T231. The invention also describes uses of the monoclonal antibody 1 G2 as well as an immunochemical detection system and the uses thereof. The invention finally describes the use of the immunochemical detection system for diagnosing Alzheimer's disease in humans.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: March 10, 2020
    Assignee: AJ ROBOSCREEN GMBH
    Inventors: Ingolf Lachmann, Max Holzer, Piotr Lewczuk, Johannes Kornhuber, Armand Perret-Liaudet, Katharina Waniek
  • Patent number: 10576129
    Abstract: The present invention discloses a nerve growth factor composition and an injection powder comprising a nerve growth factor, a stabilizer, a pH buffer, and water, wherein the stabilizer is at least one of sorbitol, dextran, trehalose, raffinose and mannitol. By using a carbohydrate or sugar alcohol as a stabilizer, the present invention can avoid the potential risk resulting from the presence of viruses or other unknown components in albumin. In addition to the nerve growth factor, only the stabilizer and the pH buffer are contained, without conventional surfactant and supporting agent, increasing safety and significantly reducing incidence of the adverse reactions. The present invention not only provides a protective effect on mNGF, but also can ensure good stability of hNGF and rhNGF in the preparation, transportation and storage processes, and has better medication safety and quality control.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: March 3, 2020
    Assignees: Staidson (Beijing) Biopharmaceuticals Co., Ltd., Beijing Staidson Medical Technology Co., Ltd.
    Inventors: Jianping Tan, Bingzhang Wang
  • Patent number: 10578629
    Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: March 3, 2020
    Assignees: GEORGETOWN UNIVERSITY, UNIVERSITY OF ROCHESTER
    Inventors: Howard J. Federoff, Mark E. Mapstone, Amrita K. Cheema, Massimo S. Fiandaca
  • Patent number: 10556947
    Abstract: Disclosed herein is use of a binding molecule which specifically binds to a precursor of brain-derived neurotrophic factor (proBDNF). The binding molecule for proBDNF, especially a monoclonal antibody against proBDNF, can be used to prevent, mitigate or treat autoimmune diseases.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: February 11, 2020
    Assignee: Shanghai Yile Biotechnology Co., Ltd.
    Inventors: Changqi Li, Huamao Wang, Ruping Dai, Xiumei Cai, Xinfu Zhou
  • Patent number: 10556946
    Abstract: Provided are novel human-derived anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and/or aggregated HTT species and or fragments thereof, as well as methods related thereto. The human-derived anti-HTT antibodies and biotechnological derivatives can be used in pharmaceutical and diagnostic compositions for HTT targeted immunotherapy of Huntington Disease and diagnosis thereof.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: February 11, 2020
    Assignee: Neurimmunie Holding AG
    Inventors: Marcel Maier, Jan Grimm
  • Patent number: 10544466
    Abstract: A method increases permeability of a blood-brain barrier in a subject. The method includes administering a small interfering ribonucleic acid (siRNA) against the 3-Phosphoinositide Dependent Protein Kinase 1 (PDPK1) gene or micro ribonucleic acid (miRNA) miR-181c as an active ingredient to the subject. The method can be applied for delivering a desired active agent to the subject.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: January 28, 2020
    Assignees: Gene Techno Science Co., Ltd., National Cancer Center, Theoria Science Inc.
    Inventors: Takahiro Ochiya, Naoomi Tominaga
  • Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • Patent number: 10525108
    Abstract: The present invention relates to methods of inhibiting neurodegeneration in a subject suffering from or genetically at risk and/or destined to develop Huntington's Disease comprising increasing, in neurons of the subject, the activity of the TIM23 mitochondrial protein import complex.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 7, 2020
    Assignees: University of Pittsburgh—Of The Commonwealth System Of Higher Education, WASHINGTON UNIVERSITY
    Inventors: Robert Friedlander, Hiroko Yano
  • Patent number: 10517830
    Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Prothena Biosciences Limited
    Inventors: Patrick Garidel, Isaac Craig Henderson, Pamela Klein